UPXI vs. MTEX, PAVS, HAPP, IMCC, BON, AKAN, SMFL, SNDL, TLRY, and CRON
Should you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Mannatech (MTEX), Paranovus Entertainment Technology (PAVS), Happiness Development Group (HAPP), IM Cannabis (IMCC), Bon Natural Life (BON), Akanda (AKAN), Smart for Life (SMFL), SNDL (SNDL), Tilray (TLRY), and Cronos Group (CRON). These companies are all part of the "medicinals & botanicals" industry.
Mannatech (NASDAQ:MTEX) and Upexi (NASDAQ:UPXI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, community ranking, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
Mannatech received 288 more outperform votes than Upexi when rated by MarketBeat users. Likewise, 75.39% of users gave Mannatech an outperform vote while only 42.86% of users gave Upexi an outperform vote.
13.0% of Mannatech shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 41.5% of Mannatech shares are held by insiders. Comparatively, 38.3% of Upexi shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Mannatech has a net margin of -1.31% compared to Mannatech's net margin of -28.34%. Upexi's return on equity of -15.37% beat Mannatech's return on equity.
Upexi has a consensus target price of $1.25, suggesting a potential upside of 211.02%. Given Mannatech's higher probable upside, analysts plainly believe Upexi is more favorable than Mannatech.
In the previous week, Mannatech had 1 more articles in the media than Upexi. MarketBeat recorded 3 mentions for Mannatech and 2 mentions for Upexi. Mannatech's average media sentiment score of 1.43 beat Upexi's score of 0.72 indicating that Upexi is being referred to more favorably in the news media.
Mannatech has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Comparatively, Upexi has a beta of 0.5, suggesting that its stock price is 50% less volatile than the S&P 500.
Mannatech has higher revenue and earnings than Upexi.
Summary
Mannatech beats Upexi on 12 of the 14 factors compared between the two stocks.
Get Upexi News Delivered to You Automatically
Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
